Squarepoint
ANRO icon

Squarepoint’s Alto Neuroscience ANRO Stock Holding History

Squarepoint’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$674K Buy
+29,961
New +$555K ﹤0.01% 3101
2025
Q4 		– Sell
-22,816
Closed -$91.7K – 5011
2025
Q3 		$91.7K Sell
22,816
-45,132
-66% -$150K ﹤0.01% 4129
2025
Q2 		$149K Buy
67,948
+51,384
+310% +$122K ﹤0.01% 4063
2025
Q1 		$35.8K Buy
+16,564
New +$59.3K ﹤0.01% 4389
2024
Q2 		– Sell
-28,369
Closed -$435K – 4744
2024
Q1 		$435K Buy
+28,369
New +$444K ﹤0.01% 3139

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Squarepoint's ANRO Position: Q1 2026 in Review

Squarepoint opened a new position in Alto Neuroscience (ANRO) in Q1 2026: 29,961 shares worth $674K. The stake represents ﹤0.01% of the portfolio and ranks #3101 among its holdings. This is a return to the name: Squarepoint previously reported a position in ANRO as recently as Q3 2025.

Squarepoint first reported a position in ANRO in Q1 2024 and has held it in 5 quarters since. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • Squarepoint held 29,961 shares of Alto Neuroscience worth $674K as of Q1 2026.
  • Alto Neuroscience was a new Squarepoint position in Q1 2026.
  • Alto Neuroscience made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3101 holding.
  • Squarepoint first reported a position in Alto Neuroscience in Q1 2024 and has held it in 5 quarters since.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.